Verolabs

Verolabs sells at-home diagnostic and wellness products that pair with a smartphone app: rapid STI tests, fertility hormone kits, vitamin-D strips, UTI screens, and a COVID/flu combo test. All items are sold direct-to-consumer through verolabs.com and ship in discreet packaging; prices sit in the mid-range bracket, with most single-use kits between $35-$79 and multi-test bundles up to $149. The brand operates online only and offers subscription re-ordering for repeat tests. The company’s core edge is CLIA-waived, FDA-cleared lateral-flow chemistry that returns clinically valid results in 15 minutes and syncs automatically to the free Vero app for encrypted sharing with physicians or partners. Each kit contains a mini-spectrometer dongle that calibrates the assay against a printed QR card, removing visual guesswork and allowing quantitative readouts from a single drop of blood, saliva, or urine. This hardware-plus-software platform has made their STI trio (HIV, syphilis, chlamydia) one of the best-selling DTC sexual-health tests in the U.S. since its 2022 launch. Customers are 20-40-year-old urban professionals who want lab-grade data without clinic wait times, co-pays, or insurance paperwork; 60 % identify as female and cite “privacy first” as the primary purchase driver. The brand speaks to sex-positive, preventative lifestyles and markets heavily on TikTok and Instagram with the tagline “Know today, live tomorrow,” aligning with values of bodily autonomy, transparency, and tech-enabled convenience. Verolabs competes in the crowded at-home diagnostics space against strip-only kits that rely on color matching and against mail-in lab services with 2-5 day turnaround. It differentiates by delivering instrument-read, physician-verified results in minutes while still undercutting traditional lab fees, and by bundling encrypted result sharing and longitudinal tracking inside one ecosystem.